UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 17,546 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 67.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,714 shares of the company's stock after purchasing an additional 17,546 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.09% of Enliven Therapeutics worth $984,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $97,000. BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $112,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at $200,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at $228,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Trading Up 11.4%

ELVN traded up $2.25 during trading on Friday, hitting $21.91. 3,224,928 shares of the company's stock traded hands, compared to its average volume of 285,750. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -11.53 and a beta of 0.79. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The company's 50 day simple moving average is $18.30 and its two-hundred day simple moving average is $20.67.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Ratings Changes

ELVN has been the subject of several recent analyst reports. HC Wainwright boosted their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 16th.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the sale, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at $20,629,865.36. The trade was a 1.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at $490,590. The trade was a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 101,111 shares of company stock valued at $1,936,664 over the last ninety days. 25.90% of the stock is currently owned by company insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.